Palma Ann Marone
Research Subjects
Palma Ann Marone has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Wallace Hayes
University of South Florida
1 shared publication Claudia Donath
From the Eurofins Product Safety Laboratories, Dayton, New Jersey (PAM); Canadian Centre for Functional Medicine, Coquitlam, British Columbia, Canada (ML, SW); University of British Columbia, Vancouver (ML); Factors R & D Technologies, Calgary, Alberta, Canada (RG); and and BSL Bioservice Scientific Laboratories GmbH, Planegg, Germany (CD, HH-H)
1 shared publication- Daniel J Merkel
Eurofins|Product Safety Laboratories, 2394 Highway 130, Dayton, NJ 08810 USA
1 shared publication - George A. Burdock
Burdock Group, 859 Outer Road Orlando, FL, 32814, USA
1 shared publication Hana Hofman-Hüther
From the Eurofins Product Safety Laboratories, Dayton, New Jersey (PAM); Canadian Centre for Functional Medicine, Coquitlam, British Columbia, Canada (ML, SW); University of British Columbia, Vancouver (ML); Factors R & D Technologies, Calgary, Alberta, Canada (RG); and and BSL Bioservice Scientific Laboratories GmbH, Planegg, Germany (CD, HH-H)
1 shared publicationMichael Lyon
From the Eurofins Product Safety Laboratories, Dayton, New Jersey (PAM); Canadian Centre for Functional Medicine, Coquitlam, British Columbia, Canada (ML, SW); University of British Columbia, Vancouver (ML); Factors R & D Technologies, Calgary, Alberta, Canada (RG); and and BSL Bioservice Scientific Laboratories GmbH, Planegg, Germany (CD, HH-H)
1 shared publication
Latest Publications
- 1 February 2014
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 68 (1) , 108-118
Reassessing the two-year rodent carcinogenicity bioassay: A review of the applicability to human risk and current perspectives
- 1 February 2014
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 68 (1) , 108-118
Reassessing the two-year rodent carcinogenicity bioassay: A review of the applicability to human risk and current perspectives
- 27 July 2009
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 28 (4) , 318-331
Genotoxicity Studies of PolyGlycopleX (PGX)
PolyGlycopleX (PGX), a novel dietary fiber, produces no mutagenic effects in bacterial tester strains Salmonella typhimurium TA 98, TA 100, TA 1535, and TA 1537 and Escherichia coli WP2 uvrA at concentrations of 0.316, 1.00, 3.16, 10.0, 31.6, and 100 μg/plate. No biologically relevant increases in revertant colonies of any of the 5 strains are observed at any concentration; however, a reduction at 100 μg/plate in TA 1537 is noted. PGX, analyzed for polychromatic erythrocyte micronuclei induction in mice following a single 1×, 0.5×, and 0.2× maximum tolerable dose intraperitoneal treatment, produces no biologically relevant increase in any dose group. Males at 1× maximum tolerable dose show a reduction of micronuclei-containing cells. High-dose animals show signs of systemic toxicity, including a reduction of spontaneous activity, rough fur, palpebral closure, prone position, and constricted abdomen. These genotoxicity studies show PGX to be nonmutagenic in both the Ames bacterial reverse mutation assay and the mammalian erythrocyte micronucleus test.
- 27 July 2009
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 28 (4) , 318-331
Genotoxicity Studies of PolyGlycopleX (PGX)
PolyGlycopleX (PGX), a novel dietary fiber, produces no mutagenic effects in bacterial tester strains Salmonella typhimurium TA 98, TA 100, TA 1535, and TA 1537 and Escherichia coli WP2 uvrA at concentrations of 0.316, 1.00, 3.16, 10.0, 31.6, and 100 μg/plate. No biologically relevant increases in revertant colonies of any of the 5 strains are observed at any concentration; however, a reduction at 100 μg/plate in TA 1537 is noted. PGX, analyzed for polychromatic erythrocyte micronuclei induction in mice following a single 1×, 0.5×, and 0.2× maximum tolerable dose intraperitoneal treatment, produces no biologically relevant increase in any dose group. Males at 1× maximum tolerable dose show a reduction of micronuclei-containing cells. High-dose animals show signs of systemic toxicity, including a reduction of spontaneous activity, rough fur, palpebral closure, prone position, and constricted abdomen. These genotoxicity studies show PGX to be nonmutagenic in both the Ames bacterial reverse mutation assay and the mammalian erythrocyte micronucleus test.
- Open Access
- 16 January 2009
- Published by Springer Nature in Nutrition Journal
- Vol. 8 (1) , 1
The safety of PolyGlycopleX® (PGX®) as shown in a 90-day rodent feeding study
This study was designed to evaluate the safety of PolyGlycopleX® (PGX®), a novel viscous dietary polysaccharide (fiber), when administered to Sprague Dawley® rats in the diet for 90 days.
- 16 January 2009
- Published by Springer Nature in Nutrition Journal
- Vol. 8 (1) , 1
Open AccessThe safety of PolyGlycopleX® (PGX®) as shown in a 90-day rodent feeding study
This study was designed to evaluate the safety of PolyGlycopleX® (PGX®), a novel viscous dietary polysaccharide (fiber), when administered to Sprague Dawley® rats in the diet for 90 days.